Effect of N-Acetylcysteine on Positive and Negative Syndrome Scale associated with Schizophrenia: A Meta-Analysis

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 253

فایل این مقاله در 11 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:


تاریخ نمایه سازی: 19 دی 1399

چکیده مقاله:

Background and objective: N-acetylcysteine (NAC), a precursor of L-cysteine with antioxidant, anti-inflammatory and neurotropic effects, is a promising agent in alleviating symptoms associated with schizophrenia.  However, the role of NAC on parameters of Positive and Negative Syndrome Scale (PANSS) remain uncertain. This systematic review and meta-analysis explored the effect of NAC on parameters of PANSS in patients with chronic schizophrenia. Methods: We searchedPubmed/MEDLINE™, PsycNET™, PsycLIT™, Scopus™ and Google Scholar™  for studies on the effect of NAC on PANSS in patients with schizophrenia from inception to March 2019. We adopted medical and non-medical subjects headings (MeSH, non-MeSH) and several keywords, including  “NAC”, “N-acetylcysteine”, “N-acetyl cysteine”, “Acetylcysteine”, “N-Acetyl-L-cysteine”,  “schizophrenia”, “psychotic disorder”, “psychosis”, “schizoaffective” and “dementia praecox”. Results: We identified seven trials with274 patients meeting the inclusion criteria, with follow up between 8-52 weeks, and NAC supplementation between 1200-3600 mg/day. Significant improvements in PANSS were identified following NAC for total (SMD=-0.61, 95% CI = -0.91, -0.31 ; P<0.001), general (SMD = -0.58; 95% CI = -0.90, -0.26; P=0.0004); and negative (SMD = -0.56; 95% CI = -0.92, -0.21; P = 0.001) scores, respectively. No significant heterogeneity was found among studies. Significant reductions were observed following sub-group analysis in trials ≤ 24 weeks duration, with appreciable effect size for total (SMD= -0.83), general (SMD= -0.67) and negative (SMD=-1.09) scores. Conclusion: Supplementation of NAC was effective in alleviating PANSS symptoms associated with schizophrenia in trials ≤ 24 weeks duration. The use of NAC as an adjunct seems promising and further investigation is warranted to determine its precise role.

کلیدواژه ها:

NAC ، Positive and Negative Syndrome Scale (PANSS) ، Schizophrenia ، Systematic review ، RCTs ، Meta-analysis


Amir Ghaderi

Department of Addiction studies, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

Anna Bussu

Faculty of Health, Social Care and Medicine, Applied Health and Social Care, Edge Hill University, Ormskirk, Lancashire, United Kingdom.

Catherine Tsang

Faculty of Health and Life Sciences, Health Applied Sciences, Northumbria University, Newcastle, United Kingdom.

Sadegh Jafarnejad

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.